Fulgent Genetics (7F0) Stock Price & Analysis
7F0 Stock Chart & Stats
- Day’s Range
- EUR 19.10 - EUR 19.10
- 52-Week Range
- EUR 11.80 - EUR 26.60
- Previous Close
- EUR 19.10
- Volume
- 0
- Average Volume (3M)
- 15
- Market Cap
- EUR 508.02M
- Enterprise Value
- EUR 321.60M
- Total Cash (Recent Filing)
- EUR 257.03M
- Total Debt (Recent Filing)
- EUR 9.42M
- Price to Earnings (P/E)
- ―
- Beta
- 0.43
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.58
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Low Leverage
Extremely low leverage and substantial liquidity provide financial flexibility while the company works through operating losses and invests in growth. This balance-sheet cushion can support acquisitions, product development, and continued operations without the same debt burden or refinancing pressure faced by highly leveraged peers.
Anatomic Pathology Growth
Rapid Anatomic Pathology growth and successful integration of Bako and StrataDX broaden Fulgent's service offering and customer reach. The expanded sales team and expected second-half contribution create a tangible platform for recurring diagnostic revenue and help offset weakness in other testing areas.
Proprietary Therapeutic Pipeline
Clinical progress in FID-007 and FID-022 gives Fulgent a potential longer-term growth avenue beyond laboratory diagnostics. Both programs use the company's patented, fully owned CleanChemo platform, preserving strategic control while upcoming clinical milestones could validate and expand this proprietary asset base.
Bears Say
Persistent Operating Losses
Revenue has remained roughly flat while losses persist, indicating that the current operating model has not yet converted scale into sustainable earnings. Continued negative margins reduce internal funding capacity, weaken returns on the large equity base, and leave profitability dependent on successful execution improvements.
Material Cash Burn
Recent cash consumption shows that reported liquidity is being used to support operations rather than replenished by the business. If losses and negative cash conversion continue, Fulgent may have less flexibility for acquisitions, therapeutic investment, repurchases, or other strategic priorities over the next several quarters.
Revenue-cycle And Volume Pressure
The revenue-cycle transition is delaying billing and weakening collections, while customer insourcing removes an important source of testing volume. Uncertain recovery timing makes revenue forecasting less reliable and, together with the lost customer demand, creates a durable execution challenge for near-term growth.
7F0 FAQ
What was Fulgent Genetics’s price range in the past 12 months?
What is Fulgent Genetics’s market cap?
When is Fulgent Genetics’s upcoming earnings report date?
How were Fulgent Genetics’s earnings last quarter?
Is Fulgent Genetics overvalued?
Does Fulgent Genetics pay dividends?
What is Fulgent Genetics’s EPS estimate?
How many shares outstanding does Fulgent Genetics have?
What happened to Fulgent Genetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fulgent Genetics?
What is the TipRanks Smart Score and how is it calculated?
Fulgent Genetics Stock Smart Score
Company Description
Fulgent Genetics
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ming Hsieh
- Employees
- 1,315
- Website
- www.fulgentgenetics.com
- Address
- 4978 Santa Anita Avenue, El Monte, CA, 91731, US
Fulgent Genetics (7F0) Earnings & Revenues
7F0 Company Deck
7F0 Earnings Call
Earnings Call SentimentNeutral
The call presents a mixed picture: meaningful operational and near-term financial headwinds driven by a complex revenue-cycle transition and loss of volume from a large customer led management to reduce full-year revenue guidance and report wider losses. Offsetting these challenges are strong cash reserves, successful integration of recent acquisitions, sequential margin improvement, continued share repurchases, product and AI advancements, and tangible progress in the therapeutic pipeline (FID-007 and FID-022). The issues are material to near-term results, but the company retains financial flexibility and long-term growth drivers.
View all DE:7F0 earnings summaries7F0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 3 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |
